bit.bio
PrivateLast Round
Series C
Jan 9, 2026
Est. Valuation
$500M
Total Funding Raised
$228.92M
Company Overview
bit.bio is a biotechnology company that provides human cells for research, drug discovery and cell therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
bit.bio Comparables
Compare bit.bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Axol Bioscience | 82% | |
| BrainXell | 81% | |
| Ncardia | 80% |
bit.bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 9, 2026 | ||||
| Growth Equity | Dec 16, 2024 | ||||
| Series B | Nov 5, 2021 | ||||
| Series A | Jun 13, 2020 | ||||
| Seed | Mar 27, 2019 | ||||
Seed | Nov 1, 2017 |
bit.bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Metaplanet Holdings | Series B |
| BlueYard Capital | Series A, Growth Equity |
| Prudential Assurance Company | Series C |
| ARCH Venture Partners | Series A, Growth Equity, Series B |
| ARCH Venture Partners | Growth Equity, Series A |
| M&G Investments | Series C, Growth Equity |
| Foresite Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 2, 2025
Received Platinum status in the Green Impact Awards for the second consecutive year.
- Sep 9, 2025
Attended the 13th World Congress on Alternatives and Animal Use in the Life Sciences.
Recent news
Latest coverage and updates
- partners_withSep 23, 2026
Bit Bio Ltd partnered with Myriamed on Sep 23rd '26.
- launchesAug 15, 2026
Bit Bio Ltd launches ioScreen platform, a new CRISPR screening service.
- launchesJul 6, 2026
Bit.Bio launches dedicated cell culture media kits for iPSC-derived ioGlutamatergic Neurons and ioMicroglia.
bit.bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about bit.bio's valuation, stock price, and market status.
Is bit.bio a public or private company?
bit.bio is a private company.
What is the current stock price of bit.bio?
bit.bio is a private company with no public stock price. No recent secondary market data is available.
How much is bit.bio worth (valuation)?
bit.bio's valuation is estimated at $500.0M based on funding round data.
Can I buy bit.bio stock?
bit.bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was bit.bio's last funding round?
bit.bio's most recent funding round was Series C on November 5, 2021.
Who are the main investors in bit.bio?
Key investors in bit.bio include ARCH Venture Partners, M&G Investments, Foresite Capital.
Will bit.bio IPO soon?
No public IPO plans have been announced for bit.bio.
How can I track bit.bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor bit.bio's secondary market activity and sign up for updates.